Last reviewed · How we verify
Amended LLS COVID-19 Registry — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Amended LLS COVID-19 Registry (Amended LLS COVID-19 Registry) — Blood Cancer United.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amended LLS COVID-19 Registry TARGET | Amended LLS COVID-19 Registry | Blood Cancer United | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amended LLS COVID-19 Registry CI watch — RSS
- Amended LLS COVID-19 Registry CI watch — Atom
- Amended LLS COVID-19 Registry CI watch — JSON
- Amended LLS COVID-19 Registry alone — RSS
Cite this brief
Drug Landscape (2026). Amended LLS COVID-19 Registry — Competitive Intelligence Brief. https://druglandscape.com/ci/amended-lls-covid-19-registry. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab